Cygnus Capital Advisors LLC Has $2.52 Million Holdings in Pfizer Inc. $PFE

Cygnus Capital Advisors LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 26.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 104,460 shares of the biopharmaceutical company’s stock after selling 38,340 shares during the period. Pfizer makes up approximately 1.7% of Cygnus Capital Advisors LLC’s investment portfolio, making the stock its 25th largest holding. Cygnus Capital Advisors LLC’s holdings in Pfizer were worth $2,515,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Brighton Jones LLC boosted its holdings in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC lifted its position in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. United Bank lifted its position in Pfizer by 12.4% in the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after acquiring an additional 6,415 shares in the last quarter. Sei Investments Co. boosted its stake in Pfizer by 31.5% in the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after purchasing an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC increased its holdings in Pfizer by 45.3% during the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after purchasing an additional 31,896 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

NYSE PFE opened at $28.42 on Tuesday. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The firm’s fifty day moving average price is $26.06 and its two-hundred day moving average price is $26.34. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $29.21. The firm has a market capitalization of $161.98 billion, a P/E ratio of 37.40, a price-to-earnings-growth ratio of 1.91 and a beta of 0.34.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the business earned $0.78 EPS. Pfizer’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. The ex-dividend date of this dividend was Friday, July 24th. Pfizer’s payout ratio is 226.32%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on PFE shares. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a report on Tuesday, June 9th. BMO Capital Markets decreased their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Monday, July 6th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and decreased their price target for the stock from $32.00 to $28.00 in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus price target of $28.28.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.